Axsome Therapeutics (NASDAQ:AXSM) released its earnings results on Friday. The company reported ($0.31) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.02, MarketWatch Earnings reports.
Shares of AXSM stock traded down $0.05 during mid-day trading on Friday, reaching $3.87. The company’s stock had a trading volume of 448,120 shares, compared to its average volume of 336,109. Axsome Therapeutics has a 1-year low of $2.05 and a 1-year high of $5.95. The stock has a market cap of $102.91 million, a price-to-earnings ratio of -3.12 and a beta of -0.51. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.26 and a current ratio of 2.26.
Several research firms recently commented on AXSM. ValuEngine upgraded shares of Axsome Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday. LADENBURG THALM/SH SH set a $5.00 target price on shares of Axsome Therapeutics and gave the company a “buy” rating in a research note on Wednesday, October 17th. Zacks Investment Research upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 25th. Finally, HC Wainwright set a $10.00 target price on shares of Axsome Therapeutics and gave the company a “buy” rating in a research note on Tuesday, October 9th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $10.10.
An institutional investor recently raised its position in Axsome Therapeutics stock. Alethea Capital Management LLC grew its holdings in Axsome Therapeutics Inc (NASDAQ:AXSM) by 132.5% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 270,823 shares of the company’s stock after buying an additional 154,323 shares during the quarter. Axsome Therapeutics accounts for approximately 1.5% of Alethea Capital Management LLC’s holdings, making the stock its 12th biggest holding. Alethea Capital Management LLC owned 1.05% of Axsome Therapeutics worth $867,000 at the end of the most recent quarter. Institutional investors and hedge funds own 16.70% of the company’s stock.
WARNING: This piece was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/11/10/axsome-therapeutics-axsm-announces-quarterly-earnings-results-beats-estimates-by-0-02-eps.html.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.
Further Reading: How to Invest in the Dividend Aristocrat Index
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.